Glaucoma patients may soon ditch eye drops after cataract surgery

NCT ID NCT07218796

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a bimatoprost implant placed inside the eye during cataract surgery to lower eye pressure in people with glaucoma or high eye pressure. About 400 participants will receive either the implant with a special lens or standard eye drops. The goal is to see if the implant works as well as or better than daily drops.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

bimatoprost implant

What this could lead to

If successful, this could offer a long-term, drop-free way to control eye pressure after cataract surgery for people with glaucoma.

What could go wrong

This is still in testing, so it may not work better than standard drops. There are also risks from the implant procedure itself, like infection or inflammation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • R and R Eye Research, LLC

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••